TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

BRIGHTGENE

MetabolicCardiovascularRespiratory
Generics

BRIGHTGENE is a generic drug manufacturer focused on Metabolic, Cardiovascular, Respiratory.

2019
Since
2
Drugs
-
Trials
5
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

ENTECAVIR 2024-12-23
ENTECAVIR 2024-12-23
Manufacturing (CMC)
ENTECAVIR 2024-12-19
Labeling
FONDAPARINUX SODIUM 2024-12-18
FONDAPARINUX SODIUM 2024-08-19
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 68%
0 drugs Phase 3: 4 Phase 2: 3 Phase 1: 4
Cardiovascular 16%
1 drugs
Respiratory 16%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

AstraZeneca big-pharma
Respiratory, Cardiovascular, Metabolic
Boehringer Ingelheim big-pharma
Metabolic, Respiratory, Cardiovascular
BRACCO specialty
Cardiovascular, Metabolic, Respiratory
Novartis big-pharma
Cardiovascular, Respiratory
Merck big-pharma
Cardiovascular, Metabolic